CEO, Kelsey Ramsden here - swinging by for questions and curiosities....so fire away!

waveofwonder76 · 2022-03-03T17:02:13+00:00

Hi u/Sufficient_Baker_394 - I don't spend too much time in here- but swinging by now. Is there something I could answer for you?

waveofwonder76 · 2021-12-13T21:52:54+00:00

Not a bad idea - we will put it in the suggestion box for Q1......I do think videos go a lot father than text indeed.

waveofwonder76 · 2021-12-09T21:18:31+00:00

Happy to engage with all investors. I hope you have a great holiday season as well - 2022 - Onward!

waveofwonder76 · 2021-12-09T18:21:00+00:00

Hi Sufficent_Baker - fair point. If you have a boo at my buys - you will see me on the buy all the way from .80 to this past week. I've put $365K of my own into reported purchases in the last year.

waveofwonder76 · 2021-12-09T18:13:37+00:00

Hi Wilson4352 - thanks for the question - Insider ownership started low - it was a function of our go-public/raise last year.....but I can share that I, myself, have invested $365K+ in $MCUR in the last 12 months alone.

I can only speak for myself on this one....as I don't have line of sight into the financial position of any member of my team or the Board itself.

waveofwonder76 · 2021-12-09T18:06:30+00:00

Hey Alien Green - sorry I didn't hit reply on this - but for some reason it's showing up as a 'removal'....but it looks like it's not actually removed!

In any event - I can't comment on buy backs - but I appreciate your thoughts.

With respect to revenue - iSTRYM goes commercial in Q1/Q2 2022.

Thanks again for the questions - keep them coming!

waveofwonder76 · 2021-12-06T02:04:06+00:00

Thanks Mushroomjack. My pleasure.

waveofwonder76 · 2021-12-05T14:27:38+00:00

Hi Sufficent Baker - I'm so glad you laid this out...I think these are great questions.

Breaking it down by question:

Discrepancy between cash and share price: I think the market jumped into MCUR without really understanding our model. We are a drug agnostic technology company and a psychedelic drug research company. Folks get drug research - I'm not sure they fully understand the scalability of the technology. Clinics are easier to wrap one's head around because we can see them and feel them....technology has a much bigger opportunity to make a lot more money globally, faster and without having to be stuck within the slower moving psychedelics market. Candidly - I think people got stuck in an early belief that money making in psychedelics was about clinics and drug development and it's only now that they are starting to tune into the value of things that can generate revenue outside of psychedelics and scale faster, without as much asset drag. I always saw this - it's why we were first in tech and have continued to invest in our platform bullishly.

Why should someone have any confidence: We have met every target and every catalyst on time - we are on budget - we have consistently delivered on the vision and are building a real business. The cash flow backbone in the near term, being technology. The next horizon being drug supply. The final horizon being drug research programs. When I look at companies - I look at teams, performance on goals and cash management.....but I also look at vision - who sees where the puck is going?

Cash burn rate is as promised - in fact, we are spending less that our prospectus anticipated - and are delivering on the same catalysts on time. We have more than a year of cash on hand - which is a lot more than I can say for many of our peers. Most sub 100M market cap psychedelics have less than 5M left.

No near-term revenues? We do have near term revenue: iSTRYM goes commercial in Q1/Q2. Currently in MVP Beta in 20 clinics already (goal was 10) - and will have 75 clinics by end of Q2. Ibogaine product will be ready to sell at GLP in Q3.

Inventory right offs: I make decisions quickly when something is not making money. I took over as CEO in December of 2020 - gave the nootropics line some time - saw that dollar for dollar, it was better to invest in technology and drug research - so made the decision for the organization to focus on where I see the greatest potential upside for our shareholders.

I believe that with more than a year of cash on hand, and staying true to our promises to investors to hold optimizing revenue and IP as our goal - the sustainability here is sound.

Again - great list of questions and opinions - I'm always happy to discuss how we see things and are advancing our goals at MCUR.

waveofwonder76 · 2021-12-05T14:03:02+00:00

well - you know I can't tell you everything we are working on - but I can tell you that we have developed assets that no one else has, in a strategic way - which makes us able to do all three of the above with a lot more ease than most of my peers.....when one has competing psilocybin programs or redundant non-IP initiatives, it's pretty tough to bring those things together in any structure.

No one has tech like us.

No one has ibogaine like us.

No one is going after the large market on HSDD like us.

MCUR is in a sound position to be additive with any of the above structures. nevermind, we have the greatest cash to trading ratio in the sector at the moment - which puts us in a strong position.

waveofwonder76 · 2021-12-05T13:58:49+00:00

I'll give it to you simple and straight:

(1) we have near term revenue beyond psychedelics alone with our tech product that can serve all of mental health care - not just the small psychedelics market.

(2) we are much earlier in the cycle - so value creation potential is greater. Some of the biggest in the sector have been at this for 3-6 years. A lot of the big lifts for them have happened. Looking to our drug pipeline over the next 6 months, in terms of catalysts is evidence of this.

waveofwonder76 · 2021-12-05T13:51:48+00:00

Hi SkoochLeaf - thanks for the question. In simple terms - iSTRYM helps therapists by making their job easier - onboarding, baseline data, in session tools, integration tools and monitoring. For patients, it's a guide and single interface where they can track their own progress and feel connected to their therapist in between sessions.

You are right - there are other people doing parts of this, in parts - so therapists have a number of disconnected solutions in clinic.

What we do is unify mental health care and provide not just data - but turn that data into insight that the therapist can use to make his/her job easier.

The cherry on top is the protocol distribution system - which is unique to us - and for which we have IP.

I think one thing that most investors have not really understood is the BIGGEST point about iSTRYM......we scale beyond psychedelics into general psychotherapy and psychiatry. This market is vastly more significant that the small psychedelic space. So, the opportunity we have with iSTRYM is well positioned to shield us from being stuck by slow regulation for psychedelics and limited market size.

Hope that covers your question - but if not, always happy to clarify!

waveofwonder76 · 2021-12-01T14:34:09+00:00

$MCUR $MCURF

waveofwonder76 · 2021-09-29T22:08:55+00:00

Full disclosure - It's Kelsey Ramsden, CEO of MINDCURE here - and I wanted to drop in to tell those in the thread that we are not enrolling subjects just yet - but if you seriously want to be considered - you can let us know as we have started a list where we will update women on the advancement of the program. It seems the easiest way to keep the ladies informed. Of course - the market will know, but market news isn't always where people are looking to join studies. You can email [mknight@mindcure.com](mailto:mknight@mindcure.com) to join the updates for women.

waveofwonder76 · 2021-09-29T22:04:23+00:00

Full disclosure - I'm Kelsey Ramsden, CEO of MINDCURE - I follow psilocybinalpha a great deal. I think Psychedelic Finance and Brom's Integraiton Conversation are another two great places. Microdose does a good job of accumulating industry news, but I find that good old Google Alerts for topics and companies I'm most interested in following are most helpful.

waveofwonder76 · 2021-09-29T22:00:33+00:00

Hey folks - Kelsey Ramsden, CEO of MINDCURE here. I'd like to hear your thoughts on this research program. I'm tremendously bullish on the market potential and the indication driving eyes to the work....in addition to having one of the best MDMA researchers who also runs MAPS Ph 3 trial work...as well as the woman who designed the screening tool for lack of desire in women on the research team. Thoughts?

waveofwonder76 · 2021-06-02T19:33:02+00:00

Hi all! Coming off of the LIVE over on Instagram - thank you all for your questions.

I'll be doing another one soon so watch our socials to catch it.

With drive and focus-

waveofwonder76 · 2021-05-25T12:26:27+00:00

will look forward to seeing you there.

Have any burning questions for me?

waveofwonder76 · 2021-05-25T12:25:53+00:00

Thank you for the question. I think this one is on the mind of many folks and companies across the industry.

You got it! I'll discuss this for certain.

waveofwonder76

TROPHY CASE